AORT

Artivion, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/06/2026

Business Summary

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

 


VALUATION

P/E

92.82

Market Cap ($M USD)

$1.10B

Forward P/E

14.38

PEG

0.03

PRICE TO SALES

2.39

PRICE TO BOOK

2.41

EV / EBITDA

20.95

5-Year Average P/E

Free Cash Flow Yield

1.17%

DCF Value

$-1.93

Graham Number

$7.16

Price to FCF

85.39

EV to FCF

101.16

Earnings Yield

1.08%

FCF Yield

1.17%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.24

Next Year EPS Growth Estimate

$1.57

Next Year Revenue Growth Estimate

$76.39B

Return on Equity (ROE)

2.66%

FREE CASH FLOW

Operating Margin

7.76%

Debt-to-Equity

0.65

Piotroski F-Score

6

Altman Z-Score

2.43

Return on Invested Capital (ROIC)

4.50%

Current Ratio

3.28

Quick Ratio

2.22

Net Debt to EBITDA

3.27

Interest Coverage

1.47

Gross Profit margin

62.94%

FCF PER SHARE

$0.27

REVENUE PER SHARE

$9.54

Gainseekers Quantitative Analysis

Summary

AORT Artivion, Inc. presents a perplexing valuation scenario. Despite a staggering Forward P/E of 16.18, the stock’s DCF value is alarmingly negative, suggesting potential overvaluation. The Graham Number further underscores this, indicating a disconnect between market price and intrinsic value. However, the Altman Z-score of 2.63 implies moderate financial stability, while a low Earnings Yield of 0.96% raises questions about its profitability. The market seems to be pricing in significant future growth, but the current fundamentals paint a mixed picture.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, Artivion is strategically positioned to leverage AI advancements in healthcare. The integration of AI could enhance product innovation and operational efficiency, crucial for maintaining competitiveness. As the sector evolves, the company's adaptability to tech shifts will be vital for sustained growth.

The Bull Case

For the discerning GARP investor, Artivion offers intriguing prospects. A robust Piotroski F-Score of 7 signals strong financial health, while a commendable ROIC of 4.29% reflects efficient capital allocation. Despite a modest FCF Yield of 1.04%, the company's operating margin of 7.39% suggests solid pricing power. These metrics collectively highlight a company with potential for value creation through disciplined management and strategic growth.

The Bear Case

Yet, the bear case cannot be ignored. Artivion's Price/Book ratio of 2.71 and Price/Sales ratio of 2.69 suggest a premium valuation that may not be justified by its current earnings. The stock's proximity to its 52-week high, coupled with a high EV to EBITDA of 21.98, indicates potential overextension. Furthermore, the negligible Earnings Yield and high Price to FCF ratio of 96.04 highlight cash flow challenges, raising red flags for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$53.00

Institutional Ownership %

1-Year Beta

1.40

Insider Buying % (6 Mo)

Distance to 52-Week High

113.78%

Distance to 52-Week Low

15.11%

EARNINGS SURPRISE %

33.33%

50-DAY SMA

$32.55

200-DAY SMA

$40.04

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.